FDA Tells DC Circ. KV Drug Compounding Wasn't A Priority
The U.S. Food and Drug Administration told the D.C. Circuit on Monday that it acted fully in its discretion when it determined cracking down on competition for bankrupt drugmaker KV Pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article